<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941251</url>
  </required_header>
  <id_info>
    <org_study_id>932012</org_study_id>
    <nct_id>NCT01941251</nct_id>
  </id_info>
  <brief_title>Navigated αTMS in Treatment-resistant Schizophrenia</brief_title>
  <acronym>nTMS_NS</acronym>
  <official_title>Navigated Alpha Frequency Transcranial Magnetic Stimulation (αTMS) in Treatment-resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niuvanniemi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niuvanniemi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since 1990s, stimulation of prefrontal cortex (PFC) has shown therapeutic effects on auditory
      hallucinations as well as negative symptoms of schizophrenia. However, previous studies have
      reported mixed or negative results. Majority of the repetitive transcranial magnetic
      stimulation (rTMS) studies to date has set the target of cortical stimulation based on scalp
      site. Recently introduced method, navigated transcranial magnetic stimulation (nTMS)
      integrates the individual MRI data, and thus allows more precise targeting on brain cortical
      regions enhancing the efficacy of rTMS. Previous EEG studies have suggested reduced alpha
      band activity in patients with schizophrenia. Some recent studies using alpha (α) EEG guided
      TMS for treating positive and negative symptoms of schizophrenia have demonstrated promising
      results.

      The aim of the study is to investigate the efficacy of navigated individualized αTMS in
      treatment-resistant patients with schizophrenia. Approximately fifty patients with DSM-IV
      schizophrenia will be enrolled in this randomized, double-blind, sham-controlled study. The
      patients will receive 13 - 15 session of αTMS to the left dorsolateral prefrontal cortex
      (DLPFC), as adjunctive therapy, for 3 weeks. We assess patients via the Positive and Negative
      Syndrome Scale (PANSS), Clinical Global Impression (CGI) and neurocognitive test battery at
      baseline, 5 days after and 3 months after treatment. Serum and plasma levels of brain derived
      neurotrophic factor (BDNF) are assayed at pre and post treatment weeks.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>at baseline,5 days after treatment, 3 months after treatment</time_frame>
    <description>change in PANSS total, positive, negative and general psychopathology sum score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Improvement scale (CGI-I)</measure>
    <time_frame>at 5 days after treatment, 3 months after treatment</time_frame>
    <description>change in patient's illness relative to baseline state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychology test battery</measure>
    <time_frame>at baseline, 5 days after treatment, 3 months after treatment</time_frame>
    <description>Neuropsychology test battery consists of 6 tests for measuring neurocognitive function.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>plasma and serum levels of Brain Derived Neurotrophic Factor (P-/S-BDNF)</measure>
    <time_frame>at baseline, 1 week after treatment</time_frame>
    <description>change in P-/S-BDNF levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Navigated individualized αTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>navigated Transcranial Magnetic Stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>navigated Transcranial Magnetic Stimulation using sham coil</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>navigated Transcranial Magnetic Stimulation</intervention_name>
    <description>individualized α frequency
left DLPFC 110% motor threshold (MT)
13-15 sessions for 3 weeks</description>
    <arm_group_label>Navigated individualized αTMS</arm_group_label>
    <other_name>TMS</other_name>
    <other_name>rTMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>navigated Transcranial Magnetic Stimulation</intervention_name>
    <description>- placebo treatment: sham coil</description>
    <arm_group_label>Sham TMS</arm_group_label>
    <other_name>TMS</other_name>
    <other_name>rTMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male righthanded inpatients, 18 to 64 years of age

          -  The diagnosis of Schizophrenia or Schizoaffective Disorder according to DSM-IV

          -  Capacity and willingness to give informed consent

          -  Patient is treatment-resistant, CGI-S 4 or more

          -  Patient is not requiring a change in antipsychotic medication 2 weeks prior to or
             during treatment

          -  No foreseeable changes in patient's smoking habits during treatment

        Exclusion Criteria:

          -  Serious somatic illness

          -  Progressive neurological illness, recent brain damage (less than 3 months ago) or
             sequela of serious brain damage

          -  Unstable epilepsy

          -  Electro convulsive therapy (ECT) less than 3 months prior to treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heli Tuppurainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Niuvanniemi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Niuvanniemi Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Niuvanniemi Hospital</investigator_affiliation>
    <investigator_full_name>Heli Tuppurainen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>Repetitive Transcranial Magnetic Stimulation</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Treatment</keyword>
  <keyword>Negative Symptoms</keyword>
  <keyword>Positive Symptoms</keyword>
  <keyword>TMS</keyword>
  <keyword>rTMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

